SCHEMBL260657

SCHEMBL260657

CCC(C(=O)O)c1c(Br)[nH]c2cccc([N+](=O)[O-])c12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.40
TSHR P16473 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
AKR1C3 P42330 3/20 0.39
AKR1C2 P52895 3/20 0.39
FBP1 P09467 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
CNR2 P34972 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
APEX1 P27695 1/20 0.34
GRM8 O00222 1/20 0.34
GRM4 Q14833 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260240 0.85 FBP1 (0.41) CYP1A2TSHRMEN1KMT2APOLB
SCHEMBL260830 0.80 MGAM (0.42) CYP1A2TSHRKMT2AMAPTAKR1C3
SCHEMBL260831 0.80 MGAM (0.42) CYP1A2TSHRKMT2AMAPTAKR1C3
SCHEMBL2884256 0.76 APEX1 (0.43) CYP1A2TSHRMEN1KMT2AMAPT
SCHEMBL260294 0.76 CYP1A2 (0.45) CYP1A2TSHRMEN1KMT2AMAPT
SCHEMBL261419 0.73 LMNA (0.42) TSHRMEN1KMT2AMAPTFBP1
SCHEMBL597398 0.71 GPR17 (0.41) MEN1KMT2AMAPTSMN1; SMN2TDP1
SCHEMBL6007713 0.71 TDP1 (0.52) TSHRMEN1KMT2APOLBMAPT
SCHEMBL27691840 0.71 BCL9 (0.46) CYP1A2TSHRMEN1KMT2APOLB
SCHEMBL4656906 0.69 CYP1A2 (0.52) CYP1A2TSHRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163752-B2 Tricyclic anilide heterocyclic CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-04-24 US disclosed
US-8133891-B2 Tricyclic anilide spirolactam CGRP receptor antagonists Merck, Sharp & Dohme Corp. (US) 2012-03-13 US disclosed